ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
ImmunityBio, Inc. (IBRX)
Company Research
Source: Business Wire
Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patientsSingle apheresis yields up to 5 billion (5×109) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patientManufacturing and cryo-banking process established with finished dosage form of M-ceNK cells available within 12 days from apheresisM-ceNK cells successfully cryopreserved with demonstration of retained cytotoxicity against multiple tumor cell linesMethods now established in readiness for manufacturing in AI-driven automated robotic systems (NANT Leonardo)Combination of M-ceNK with ANKTIVA® successfully completed in Phase 1 safety study (QUILT 3.076) CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, reproducible, and scalable le
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of ‘World Bank of NK Cells' [Yahoo! Finance]Yahoo! Finance
- Is It Too Late To Reassess ImmunityBio (IBRX) After Its 315% Year To Date Surge [Yahoo! Finance]Yahoo! Finance
- IBRX Stock: Anktiva's Approvals and What Comes Next [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (IBRX) had its "buy" rating reaffirmed by BTIG Research. They now have a $13.00 price target on the stock.MarketBeat
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 2/26/26 - Form 4
- 2/25/26 - Form SCHEDULE
- 2/24/26 - Form 4
- IBRX's page on the SEC website